A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
HOME > REGULATORY
REGULATORY
- LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
- LDP Panel Backs Support for Drug Wholesalers in Economic Package
November 10, 2025
- Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
- Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
- Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
- MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
- Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- Tepid Exchanges at Chuikyo over Public-Private Working Group Report
November 6, 2025
- Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
- Japan Launches Growth Strategy Council, Sets Drug Discovery as Priority Field
November 5, 2025
- MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
November 5, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- Former Flagship Brands among 506 Drugs Set for Delisting
November 4, 2025
- Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
- Health Minister Vows to Balance Public Burden, Innovation, and Supply in FY2026 Revision
October 31, 2025
- LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
- Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
ページ
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…